Hypocellular myelodysplastic syndromes (h-MDS): from clinical description to immunological characterization in the Italian multi-center experience

TO THE EDITOR: Myelodysplastic Syndromes (MDS) are a highly heterogeneous group of blood neoplasias characterized by myeloid dysplasia, ineffective hematopoiesis and increased risk of progression to acute myeloid leukemia [1]. We focused on hypocellular-MDS (h- MDS), a rare subtype accounting for 10 – 15% of MDS patients, that is de ﬁ ned by an age-adjusted reduction of bone marrow (BM) cellularity or, according to Aplastic Anemia de ﬁ nition, by a BM cellularity <30% [2]. Although the WHO classi ﬁ cation of myeloid neoplasms and acute leukemia does not recognize h-MDS as a distinct entity, these patients are typically younger and characterized by more

TO THE EDITOR: Myelodysplastic Syndromes (MDS) are a highly heterogeneous group of blood neoplasias characterized by myeloid dysplasia, ineffective hematopoiesis and increased risk of progression to acute myeloid leukemia [1]. We focused on hypocellular-MDS (h-MDS), a rare subtype accounting for 10-15% of MDS patients, that is defined by an age-adjusted reduction of bone marrow (BM) cellularity or, according to Aplastic Anemia definition, by a BM cellularity <30% [2].
Although the WHO classification of myeloid neoplasms and acute leukemia does not recognize h-MDS as a distinct entity, these patients are typically younger and characterized by more severe cytopenias, higher transfusion dependence and lower blast percentages as compared to normo/hypercellular MDS (n-MDS) [3][4][5]. Data on h-MDS outcome, instead, are still inconsistent [4,6]. Beside these clinical features, h-MDS share molecular characteristics, including karyotype abnormalities, that suggest a common underlying pathogenesis [4,5].
A barely understood biology, ill-defined diagnostic criteria and the lack of conclusive prognostic data hindered the establishment of specific treatment guidelines for h-MDS. The evaluation of clinical outcome following immunosuppressive therapy (IST) in MDS patients indicated peculiar responses in the hypoplastic category [7,8], supporting a pathogenetic role of immune system alterations. In this regard, the immunological characterization of h-MDS should help to improve the risk stratification of patients and choice of therapy.
Taking advantage of the National Registry of the Italian Foundation of MDS (FISiM), we evaluated clinical features, overall survival (OS) and treatment of h-MDS in comparison with n-MDS. A cohort of 1945 MDS patients, enrolled in the FISiM registry, was included in the study. Patients were selected based on the availability of bone trephine biopsy evaluation and complete clinical annotations. Diagnosis of h-MDS was assumed for BM cellularity ≤30% and the prognostic stratification of patients was defined according to the Revised International Prognostic Scoring System (IPSS-R) [9].
Within the main cohort, 336/1945 (17%) patients were recognized as h-MDS and 1609/1945 (83%) as n-MDS. The age of patients ranged between 18 to 106 years, with a global M/F ratio of 1.56. According to BM cellularity, median age was 75 and 74 years in the h-MDS and n-MDS groups, respectively; the M/F ratio was 1.14 in h-MDS and 1.67 in n-MDS (p < 0.01).
Median OS was 77 months for h-MDS and 56 months for n-MDS (p > 0.05). According to IPSS-R stratification and BM cellularity, LR h-MDS had a median OS of 125 months, while LR n-MDS of 74 months (p < 0.001). Conversely, median OS in HR MDS was comparable, i.e. 19 months in HR h-MDS patients vs 20 months in n-MDS cases (p > 0.05) (Fig. 1B).
Beyond its clinical relevance, our observations provide reliable data on h-MDS outcome, possibly clarifying previously reported inconsistencies [4,10]. Most importantly, this evidence suggests that discrete biological features might account for the divergent course of the disease.
MDS are known to be characterized by a wide spectrum of immunological deregulations [1], including the frequent expansion of LGL clones, reaching the diagnostic criteria of LGL Leukemia (LGLL) in up to 27% of cases [11,12]. This prompted us to better characterize the immunological landscape of h-MDS patients, at the time of diagnosis, focusing on cytotoxic T and NK cell subsets.
A restricted subgroup of 12 h-MDS patients was enrolled within the FISiM-hMDS14 sub-study (Supplementary Table 1), to investigate the immune mechanisms in this peculiar disease subset. The study was approved by local ethic committees and patients signed informed consent, according to the Helsinki Declaration.
The immunophenotypic characterization of NK cell compartment showed CD3−/CD16 bright /CD56 dim/neg NK cell expansions in 4/12 (33%) h-MDS cases (range: 19-30% and 19-22% of lymphocytes in PB and BM, respectively), as compared to physiologic condition (range: 13 ± 5% and 6 ± 5% of lymphocytes in PB and BM, respectively) (Supplementary Table 2). NK cells were characterized by an effector-memory phenotype, based on the expression of CD57 and lack of CD62L. Evaluation of Killer Immunoglobulin-like receptors (KIR) confirmed a restricted pattern of expression, characterized by the prevalent expression of CD158b (i.e. KIR2DL2/L3) in all the 4 cases (range: 70-78% of CD3-CD16 + NK cells); of these, 3/4 (75%) were also characterized by the expression of the activating NKG2C receptor (Supplementary Table 2). As for clonal T cell proliferations, KIR restrictions in NK cell populations were detected both in PB and BM samples.
In line with previous reports, we observed that the immunological landscape of h-MDS patients is characterized by T and NK cell expansions [5,13]. The novelty of our findings relies on the dominant involvement of different LGL subsets, according to patient prognostic stratification. In detail, 5/6 (83%) patients with a T-cell clone were included among the HR group, while only 1/6 (17%) was placed in the LR category. Conversely, 3/4 (75%) patients with a NK cell clonal expansion were included in the LR group, while 1/4 (25%) fell in the HR category (Fig. 2). Although our findings need to be confirmed in a larger number of cases, the observed immunological differences could be at the basis of the improved OS that we exclusively observed in the LR h-MDS group.
We previously reported the coexistence of T cell clones in~50% of patients with chronic lymphoproliferative disorder of NK cells (CLPD-NK) [14]. In h-MDS patients, instead, no contemporary detection of TCR or KIR restriction was observed (Fig. 2), suggesting that T and NK clonal expansions may be mutually exclusive. This different involvement of T or NK cell subsets hints at distinct functional events taking place along h-MDS course, reminding the impairment of NK cell activity involved in n-MDS progression [1].
At a molecular level, we observed the presence of STAT3 activating mutations in PBMC and BMMC of 2/12 (17%) h-MDS cases (Supplementary Table 1). STAT3 mutated patients were those who fulfilled the diagnostic criteria of LGLL and they were both characterized by a monoclonal TCRɑβ/CD3+/CD4−/CD8 +/CD16+/CD56−/CD57+T-LGL expansion and included in the HR group. Based on this evidence, STAT3 mutations might be associated with a worse prognosis with respect to STAT3 wild- type cases, as in LGLL patients [15]. Consistently, STAT3 mutated T cytotoxic clones may promote a chronic inflammatory BM environment and a persistent deregulated immune activation, leading to disease progression in a discrete subset of h-MDS cases.
In line with this consideration, different hypotheses have been proposed to explain the peculiar association between LGL and myeloid clones [11]. This is quite rare, possibly representing an extreme condition caused by common age-related pathogenetic mechanisms (i.e. a pro-inflammatory environment and mutational stress). Otherwise, LGLL may evolve from an immune surveillance reaction, with aberrant hematopoietic stem cells (HSC) triggering LGL activation and clonal expansion; on the contrary, clonal LGL might themselves promote a damage in the HSC compartment, leading to MDS development.
Beyond their pathogenetic role, the observed immune alterations may have relevant clinical implications, supporting the rationale for the administration of immunosuppressive agents. In our cohort, we observed that IST is rarely applied, irrespective of BM cellularity. In detail, immunosuppressive treatments were employed for 0.4% and 1.2% of LR h-MDS and n-MDS, respectively (Supplementary Table 3). Notwithstanding, our results in h-MDS suggest that treatment with immunosuppressive agents could be an effective strategy in this disease subset. Most importantly, the immunological features of h-MDS patients may be involved in the mechanism and duration of treatment responses.
In conclusion, we report an unbiased clinical analysis of the FISiM registry, based on the largest series of h-MDS (336 patients) so far evaluated, in comparison with an extended cohort of n-MDS. Of note, we showed a significant longer OS in LR h-MDS vs LR n-MDS.
In a preliminary investigation of h-MDS patients, combining phenotypic and molecular analyses, the LR group resulted to be characterized by KIR/NKG2 restricted NK cell expansions, whereas HR h-MDS were associated with T cell clones. Prospective studies are ongoing to better define the prognostic roles of the different LGL subsets in these patients. Remarkably, our observations might pave the way for the establishment of prospective trials to evaluate the efficacy of IST in h-MDS patients and the modulation of their T and NK cell repertoire.